![]() |
|
|
Vol. 53, Issue 1, 123-127, January 1998
Institut für Pharmakologie, Freie Universität Berlin, Thielallee 69-73, D-14195 Berlin, Germany
| |
Summary |
|---|
|
|
|---|
The signaling molecule nitric oxide (NO) mediates many of its effects by the stimulation of soluble guanylyl cyclase (sGC). The activation process is initiated by high-affinity binding of NO to the enzyme's prosthetic heme group. Despite its poor sGC-activating properties, carbon monoxide (CO) has also been suggested as a physiological activator of sGC. Recently, we have shown that the substance YC-1, a benzyl indazole derivative, stimulates sGC by 10-fold (independently of NO) potentiates the stimulatory effect of NO, and turns CO into a potent activator of sGC. In the present study, we show that activation of sGC by protoporphyrin IX, a ligand-independent activator, was potentiated by YC-1, yet a shift of the concentration-response curve as seen with NO and CO was not observed. YC-1 slowed down the dissociation rates for NO and CO from the activated enzyme as monitored by cGMP accumulation after addition of the NO and CO scavenger oxyhemoglobin. A direct interaction of YC-1 with the heme group can be ruled out because YC-1 did not change the Soret absorption of basal or stimulated sGC and, in addition, still bound to the heme-depleted enzyme. Together, our results indicate that YC-1 increases the maximal catalytic rate and sensitizes the enzyme toward its gaseous activators by binding to an allosteric site on sGC molecules, thereby reducing the ligand dissociation rate from the heme group.
| |
Introduction |
|---|
|
|
|---|
The
intra- and intercellular signal molecule NO has been implicated in a
wide range of physiological functions, including neurotransmisson,
vasorelaxation, and inhibition of platelet aggregation (Ignarro
et al., 1987
; Garthwaite et al., 1988
; Moncada
and Higgs, 1995
). Many of the effects of NO are mediated by the enzyme
sGC (Waldman and Murad, 1987
; Garbers and Lowe, 1994
). By synthesis of
cGMP, sGC produces an intracellular messenger molecule that is able to
exert a variety of effects depending on the cGMP-dependent effector
system(s) (e.g., cGMP-dependent kinases, cGMP-regulated phosphodiesterases, cGMP-gated channels) present in a given cell type.
The formation of cGMP can also be catalyzed by membrane-bound GCs that
belong to the group of receptor-linked enzymes and are regulated by
different peptide hormones.
In contrast to the membrane-bound GC possessing a homomeric structure,
sGC consists of two different subunits and contains a prosthetic heme
group that mediates the up-to-400-fold activation by NO (Humbert
et al., 1990
; Stone and Marletta, 1996
). NO-induced activation is thought to proceed via binding of NO to the heme iron,
breaking of the His-Fe bond, and subsequent conformational change of
the enzyme. In accordance with this mechanism of activation, PP-IX, the
iron-free precursor of heme, stimulates sGC independently of NO
(Ignarro et al., 1982
; Ignarro et al., 1984
).
Another gaseous molecule, CO, has been discussed as a putative
activator of sGC. CO has been assumed to participate in long-term potentiation (Zhuo et al., 1993
; Stevens and Wang, 1993
),
olfactory signal transduction (Verma et al., 1993
;
Leinders-Zufall et al., 1995
; Ingi and Ronnett, 1995
), and
vasorelaxation (Utz and Ullrich, 1991
; Morita et al., 1995
;
Zakhary et al., 1996
). Yet the proposal of CO as a
physiological activator of sGC is opposed by the rather poor
sGC-stimulatory properties of CO (Brüne and Ullrich, 1987
; Stone
and Marletta, 1994
).
Recently, we were able to show that the new substance YC-1, a benzyl
indazole derivative, turns CO into a potent activator of sGC (Friebe
et al., 1996
). In the presence of this substance, CO led to
a 100-fold increase in enzyme activity, which is comparable to the
stimulatory effect induced by NO. YC-1, which had been identified as an
inhibitor of platelet aggregation (Ko et al., 1994
; Wu
et al., 1995
), led to a ~10-fold activation of the
nonstimulated, purified enzyme and potentiated NO- and CO-induced
stimulation. In addition to an increase in maximal activity, YC-1 led
to a leftward shift of the concentration-response curve. Recently, cGMP-increasing effects of YC-1 have been reported in smooth muscle cells and an increase in responsiveness toward NO has been demonstrated (Mülsch et al., 1997
). In general, modulation of sGC
sensitivity toward NO and CO implies important pharmacological and
physiological functions.
This study was performed to further elucidate the mechanism of YC-1 action. YC-1 did not alter the Soret absorption of sGC, which adds to the argument against a direct interaction of YC-1 with the enzyme's prosthetic heme group. Our data demonstrate that YC-1 binds independently of the activation state of the enzyme and even to the heme-deficient enzyme, which indicates an allosteric site. We show that although YC-1 increases PP-IX-induced sGC activity, it does not shift the concentration-response curve as it does for the gaseous ligands. Additional results suggest a reduction of the dissociation rate of the heme ligand as the underlying mechanism of the YC-1-induced sensitization of sGC.
| |
Materials and Methods |
|---|
|
|
|---|
Purification of soluble guanylyl cyclase and determination of
guanylyl cyclase activity.
sGC was purified from bovine lung to
apparent homogeneity by an immunoaffinity purification procedure as
described previously (Humbert et al., 1990
). Cyclase
activity was measured by the conversion of
[
-32P]GTP to
[32P]cGMP at 37° for 10 min. Reaction
mixtures contained 3 mM Mg2+ as
divalent metal ion, 3 mM dithiothreitol, 0.5 mg/ml bovine serum albumin, 1 mM cGMP, 300 µM GTP and 50 mM triethanolamine hydrochloride, pH 7.4, in a total volume
of 0.1 ml. Reactions were stopped by ZnCO3
precipitation, and [32P]cGMP was isolated as
described (Schultz and Böhme, 1984
). All measurements were
performed in duplicates and repeated at least three times.
Synthesis of oxyhemoglobin. Oxyhemoglobin was prepared in 50 mM triethanolamine-HCl, pH 7.0, by reducing bovine methemoglobin with sodium dithionite. Subsequently, reduced hemoglobin was desalted by passing over a Sephadex G-25 (PD-10) column (Pharmacia, Freiburg, Germany). The concentration of oxyhemoglobin was determined photometrically.
Materials.
YC-1
[3-(5
-hydroxymethyl-2
-furyl)-1-benzyl
indazole] was a generous gift from Bayer (Wuppertal, Germany). DEA-NO
was purchased from Research Biochemicals (Natick, MA). Hemoglobin and
PP-IX were obtained from Sigma, and Tween 20 was purchased from
Boehringer Mannheim (Mannheim, Germany).
[
-32P]GTP (800 Ci/mmol) was from DuPont-New
England Nuclear (Boston, MA). CO gas (100% as well as 1000 parts per
million in N2) was from AGA Gas, Berlin, Germany.
| |
Results |
|---|
|
|
|---|
We previously demonstrated that YC-1 shifts the concentration-response curve for NO and CO to the left. This shift of the EC50 indicates an increase in affinity of the gaseous ligands to the enzyme's prosthetic heme group. Here, we investigated whether YC-1 was able to also shift the concentration-response curve for PP-IX. The iron-free heme precursor stimulates sGC independent of a gaseous ligand. Fig. 1 shows that the concentration-dependent activation of sGC by PP-IX was potentiated by YC-1, yielding a maximal increase in enzyme activity of 360%. However, a leftward shift of the EC50 could not be detected (Fig. 1, inset).
|
As shown earlier (Friebe et al., 1996
), YC-1 activates sGC
by an NO-independent but heme-dependent mechanism. To determine whether
YC-1 binds to the prosthetic heme group, we recorded UV-visual spectra
of sGC under nonstimulated and stimulated conditions (Fig. 2). The presence of YC-1 resulted in no
change of the Soret band of either the non-stimulated (431 nm), the
CO-stimulated (423 nm), or the NO-stimulated enzyme (398 nm; not
shown). Hence, it is unlikely that YC-1 binds to the prosthetic heme
group of the enzyme.
|
Next, we intended to explore whether YC-1 binding requires the presence of the heme group or the activated state of sGC or, alternatively, whether YC-1 binds to the nonactivated or even heme-depleted form of the enzyme. Because of the low affinity of YC-1 for sGC, we had to investigate binding of YC-1 by monitoring enzyme activity, taking advantage of YC-1's slow dissociation under NO-stimulated conditions (Table 1). Preincubation of sGC with 100 µM YC-1 under stimulated conditions (1 µM DEA-NO) in the absence of substrate and subsequent 5-fold dilution showed an increase in enzyme activity caused by the preincubation. This increasing effect of YC-1 preincubation can only be explained by the slow dissociation of YC-1 from sGC upon dilution.
|
Next, we preincubated sGC with 100 µM YC-1 under nonactivated conditions, diluted the enzyme, and, subsequently, detected bound YC-1 under stimulated conditions (0.2 µM DEA-NO) (Fig. 3A). Preincubation with YC-1 led to a 27% increase in NO-stimulated cGMP production compared with control (i.e., preincubation with buffer alone). Thus, YC-1 also binds to nonactivated sGC molecules.
|
To find out whether the heme group is required for YC-1 binding, we
performed the same set of experiments using heme-depleted sGC (Fig.
3B). In previous reports, we showed that 0.5% Tween 20 leads to the
removal of heme from the enzyme. Heme-deficient sGC still has basal
activity and can be stimulated by PP-IX (Foerster et al.,
1996
; Friebe et al., 1997
). Because YC-1 does not lead to
activation of the heme-deficient sGC, we had to stimulate the enzyme
with PP-IX and detected bound YC-1 by its potentiating effect. Fig. 3B
shows that YC-1 preincubation of the heme-depleted enzyme resulted in
an 33% increase in cGMP production. Taken together, YC-1 preincubation
resulted in an increase in sGC activity regardless of the state of the
enzyme (activated, nonactivated, or heme-depleted). These results
reinforce the spectral data in Fig. 2, and indicate that YC-1 binds to
an allosteric site on sGC.
Next, we performed experiments to explain the observed YC-1-induced
increase in affinity toward NO and CO. We hypothesized a YC-1-mediated
decrease in the dissociation rate for the gaseous ligands and
investigated the effect of YC-1 on the dissociation of NO from the heme
group of sGC by monitoring cGMP forming activity in the presence of
oxyHb, a scavenger of both NO and CO. Fig. 4 shows the accumulation of cGMP over a
time range of 10 min. After 3 min of incubation, either buffer, oxyHb,
or the nonionic detergent Tween 20 were added and incubation was
continued for another 7 min. As stated above, Tween 20 removes the heme
from sGC (Foerster et al., 1996
; Friebe et al.,
1997
). In the absence of YC-1, neither oxyHb nor Tween 20 had a
significant influence on nonstimulated cGMP synthesis (Fig. 4A,
open symbols, inset). NO-stimulated cGMP
synthesis (10 µM DEA-NO; Fig. 4A, closed
symbols) was reduced to basal levels by both oxyHb and Tween 20.
|
Presence of YC-1 (200 µM; Fig. 4B) led to a 10-fold
increase in non-stimulated cGMP production that was not affected by
oxyHb. As we have shown before (Friebe et al., 1996
),
removal of the prosthetic heme group by Tween 20 results in the
abolishment of YC-1 stimulation. Under stimulated conditions (10 µM DEA-NO; Fig. 4B, closed symbols)
and in the presence of YC-1, oxyHb was not able to completely reverse
NO stimulation as observed in the absence of YC-1 (Fig. 4A). Because
oxyHb was used in large molar excess over NO, we conclude a decreased
dissociation of NO from sGC as the reason for the diminished inhibition
by oxyHb.
Similar experiments were performed using CO instead of NO. As CO
stimulation of sGC in the absence of YC-1 is only marginal, these
experiments were only carried out in the presence of YC-1. Moreover,
the dissociation rate of CO from sGC has been reported to be very fast
(Kharitonov et al., 1995
), and therefore one would expect
immediate inhibition of CO-induced stimulation by oxyHb. As can be seen
in Fig. 5 in the presence of YC-1,
submaximally effective CO (1000 parts per million) led to a linear
increase in cGMP formed over 10 min. Addition of Tween 20 after 3 min
abolished stimulation, resulting in basal increase in cGMP formation
for the remaining 7 min. As seen with NO, administration of oxyHb led
to a partial inhibition of CO-stimulated cGMP synthesis but did not
abolish the stimulatory effect, which indicates a reduced off-rate not
only for NO but also for CO.
|
| |
Discussion |
|---|
|
|
|---|
The novel compound YC-1 sensitizes sGC for its physiological
activator NO and also turns CO into a potent activator (Friebe et
al., 1996
). Both findings have potential pharmacotherapeutic and
physiological implications. Here, we further investigated the effect of
YC-1 and its mechanism of action. By spectrophotometric analysis, we
studied the possible interaction of YC-1 with the prosthetic heme group
of sGC. As YC-1 exerts its influence, especially on the activated form
of the enzyme, spectra were also recorded in the presence of NO and CO.
Although both gases bind to the sixth position of the heme iron, only
binding of NO results in the formation of a five-coordinated complex by
breaking of the His-Fe bond. Binding of CO is thought to result in a
six-coordinated heme with the His-Fe bond remaining intact. In the
light of the highly stimulatory properties of CO in the presence of
YC-1, it was tempting to speculate on the formation of a
five-coordinated heme similar to that induced by NO, reflecting a
single activated state of sGC molecules. Nevertheless, we were not able
to detect any YC-1-induced changes in absorbance in the basal (431 nm), NO-stimulated (398 nm), or CO-stimulated (423 nm) enzyme, a finding that argues against an interaction of YC-1 with the heme group.
We wanted to define further the binding requirements for YC-1. YC-1 dilution experiments, originally performed to study the reversibility of the YC-1 action, revealed a relatively slow dissociation of YC-1 from sGC. To find out whether YC-1 bound to the nonactivated enzyme, we incubated sGC with YC-1 and detected bound YC-1 after dilution by determination of enzyme activity under stimulated conditions. Preincubation with YC-1 and subsequent dilution resulted in an elevation of enzyme activity. Even when we used a heme-depleted enzyme, YC-1 preincubation induced an increase in catalytic rate. These results indicate that YC-1 binds to sGC independent of its activation state and also independent of the heme group. These results are reinforced by the spectral data in Fig. 2.
Although YC-1 shifted the concentration-response curve for NO and CO to the left, it failed to do so for PP-IX. However, potentiation of PP-IX-stimulation (360%) was still very pronounced. As PP-IX activates the enzyme independently of a gaseous ligand, we conclude that YC-1 indeed exerts two effects on sGC: first, it potentiates the action of different activators, increasing Vmax by a still unknown mechanism. Second, YC-1 changes the affinity of the gaseous activators.
A leftward shift of the EC50 could be caused by a reduction of the dissociation rate of NO from the heme. Therefore, we investigated the effect of YC-1 on the dissociation rate of NO with the help of the NO scavenger oxyHb. The results are summarized in Fig. 4. In the absence of YC-1, NO activation of sGC is immediately abolished by the addition of oxyHb. Because oxyHb is supposed to react only with free NO, our results suggest that during NO stimulation, NO shuttles on and off the enzyme. In contrast, in the presence of YC-1, addition of oxyHb decreased NO-stimulated enzyme activity only slowly. The immediate reduction of NO-stimulated cGMP accumulation to basal level after the removal of the prosthetic heme group by Tween 20 underlines the prerequisite of the heme group for the YC-1 effect.
Similar to NO, CO has a very high affinity for heme groups, yet the
off-rate of CO from heme, in general considered to be much faster than
that of NO, has been shown to be exceptionally high for sGC (Kharitonov
et al., 1995
; Stone and Marletta, 1996
). Thus, the fast
dissociation of CO from the heme could account for the low stimulatory
properties of CO. Obviously, YC-1 dramatically reduces the CO
dissociation rate, as the CO scavenger oxyHb only leads to partial
reversal of enzyme stimulation. We conclude that reduction of the
dissociation rate of both gaseous ligands, NO and CO, represents part
of the underlying mechanism of YC-1 action.
Taken together, YC-1 enhances the activity of the stimulated enzyme independently of the type of activator used and increases the affinity for heme ligands by reduction of their dissociation rates. Because of the lack of change in absorbance spectra, a direct interaction of YC-1 with the heme group of sGC is unlikely and, because YC-1 also binds to the heme-deficient sGC, we conclude that YC-1 binds to an allosteric site on sGC. Further experiments have to show whether this allosteric site can be used by physiologically or pharmacotherapeutically relevant compounds.
| |
Acknowledgments |
|---|
We are grateful to Drs. J.-P. Stasch and R. Kast at Bayer (Wuppertal, Germany) for the generous gift of YC-1, to Dr. G. Schultz for critical reading of the manuscript, and to J. Malkewitz for purification of soluble guanylyl cyclase.
| |
Footnotes |
|---|
Received May 7, 1997; Accepted September 23, 1997
This work was supported by the Deutsche Forschungsgemeinschaft.
Send reprint requests to: Dr. Doris Koesling, Institut für Pharmakologie, Thielallee 69-73, D-14195 Berlin, Germany.
| |
Abbreviations |
|---|
NO, nitric oxide; sGC, soluble guanylyl cyclase; CO, carbon monoxide; PP-IX, protoporphyrin IX; DEA-NO, 2,2-diethyl-1-nitroso-oxyhydrazine; oxyHb, oxyhemoglobin.
| |
References |
|---|
|
|
|---|
1 and
1 subunits.
Eur J Biochem
240:
380-386[Medline]. This article has been cited by other articles:
![]() |
X. Hu, L. B. Murata, A. Weichsel, J. L. Brailey, S. A. Roberts, A. Nighorn, and W. R. Montfort Allostery in Recombinant Soluble Guanylyl Cyclase from Manduca sexta J. Biol. Chem., July 25, 2008; 283(30): 20968 - 20977. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Roy, E. J. Halvey, and J. Garthwaite An Enzyme-linked Receptor Mechanism for Nitric Oxide-activated Guanylyl Cyclase J. Biol. Chem., July 4, 2008; 283(27): 18841 - 18851. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. G. Abraham and A. Kappas Pharmacological and Clinical Aspects of Heme Oxygenase Pharmacol. Rev., March 1, 2008; 60(1): 79 - 127. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Winger, E. R. Derbyshire, and M. A. Marletta Dissociation of Nitric Oxide from Soluble Guanylate Cyclase and Heme-Nitric Oxide/Oxygen Binding Domain Constructs J. Biol. Chem., January 12, 2007; 282(2): 897 - 907. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Duranski, J. W. Elrod, J. W. Calvert, N. S. Bryan, M. Feelisch, and D. J. Lefer Genetic overexpression of eNOS attenuates hepatic ischemia-reperfusion injury Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H2980 - H2986. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Garthwaite, K. Bartus, D. Malcolm, D. Goodwin, M. Kollb-Sielecka, C. Dooldeniya, and J. Garthwaite Signaling from blood vessels to CNS axons through nitric oxide. J. Neurosci., July 19, 2006; 26(29): 7730 - 7740. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Chlopicki, R. Olszanecki, E. Marcinkiewicz, M. Lomnicka, and R. Motterlini Carbon monoxide released by CORM-3 inhibits human platelets by a mechanism independent of soluble guanylate cyclase Cardiovasc Res, July 15, 2006; 71(2): 393 - 401. [Abstract] [Full Text] [PDF] |
||||
![]() |
E.-J. Yeo, J.-H. Ryu, Y.-S. Chun, Y.-S. Cho, I.-J. Jang, H. Cho, J. Kim, M.-S. Kim, and J.-W. Park YC-1 Induces S Cell Cycle Arrest and Apoptosis by Activating Checkpoint Kinases. Cancer Res., June 15, 2006; 66(12): 6345 - 6352. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Schindler, H. Strobel, K. Schonafinger, W. Linz, M. Lohn, P. A. Martorana, H. Rutten, P. W. Schindler, A. E. Busch, M. Sohn, et al. Biochemistry and Pharmacology of Novel Anthranilic Acid Derivatives Activating Heme-Oxidized Soluble Guanylyl Cyclase Mol. Pharmacol., April 1, 2006; 69(4): 1260 - 1268. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Gocmen, H. S. Buyuknacar, A. Y. Kots, F. Murad, O. Kiroglu, and E. K. Kumcu The Relaxant Activity of 4,7-Dimethyl-1,2,5-oxadiazolo[3,4-d]-pyridazine 1,5,6-Trioxide in the Mouse Corpus Cavernosum J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 753 - 761. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Dumitrascu, N. Weissmann, H. A. Ghofrani, E. Dony, K. Beuerlein, H. Schmidt, J.-P. Stasch, M. J. Gnoth, W. Seeger, F. Grimminger, et al. Activation of Soluble Guanylate Cyclase Reverses Experimental Pulmonary Hypertension and Vascular Remodeling Circulation, January 17, 2006; 113(2): 286 - 295. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Wu and R. Wang Carbon Monoxide: Endogenous Production, Physiological Functions, and Pharmacological Applications Pharmacol. Rev., December 1, 2005; 57(4): 585 - 630. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Linder, L. P. McCluskey, K. R. Cole III, K. M. Lanning, and R. C. Webb Dynamic Association of Nitric Oxide Downstream Signaling Molecules with Endothelial Caveolin-1 in Rat Aorta J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 9 - 15. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Zhang, A. Beuve, and E. Townes-Anderson The Nitric Oxide-cGMP Signaling Pathway Differentially Regulates Presynaptic Structural Plasticity in Cone and Rod Cells J. Neurosci., March 9, 2005; 25(10): 2761 - 2770. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Balashova, F.-J. Chang, M. Lamothe, Q. Sun, and A. Beuve Characterization of a Novel Type of Endogenous Activator of Soluble Guanylyl Cyclase J. Biol. Chem., January 21, 2005; 280(3): 2186 - 2196. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. K. Langlais, J. A. Stewart, and D. B. Morton Preliminary characterization of two atypical soluble guanylyl cyclases in the central and peripheral nervous system of Drosophila melanogaster J. Exp. Biol., June 1, 2004; 207(13): 2323 - 2338. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Schmidt, M. Schramm, H. Schroder, F. Wunder, and J.-P. Stasch Identification of Residues Crucially Involved in the Binding of the Heme Moiety of Soluble Guanylate Cyclase J. Biol. Chem., January 23, 2004; 279(4): 3025 - 3032. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Martin, I. Sharina, A. Kots, and F. Murad A constitutively activated mutant of human soluble guanylyl cyclase (sGC): Implication for the mechanism of sGC activation PNAS, August 5, 2003; 100(16): 9208 - 9213. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Grosser and H. Schroder Aspirin Protects Endothelial Cells From Oxidant Damage Via the Nitric Oxide-cGMP Pathway Arterioscler. Thromb. Vasc. Biol., August 1, 2003; 23(8): 1345 - 1351. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Friebe and D. Koesling Regulation of Nitric Oxide-Sensitive Guanylyl Cyclase Circ. Res., July 25, 2003; 93(2): 96 - 105. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Koglin and S. Behrends A Functional Domain of the alpha 1 Subunit of Soluble Guanylyl Cyclase Is Necessary for Activation of the Enzyme by Nitric Oxide and YC-1 but Is Not Involved in Heme Binding J. Biol. Chem., March 28, 2003; 278(14): 12590 - 12597. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Behrends, A. Mietens, J. Kempfert, M. Koglin, H. Scholz, and R. Middendorff The Expression Pattern of Nitric Oxide-sensitive Guanylyl Cyclase in the Rat Heart Changes During Postnatal Development J. Histochem. Cytochem., October 1, 2002; 50(10): 1325 - 1332. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Russwurm, E. Mergia, F. Mullershausen, and D. Koesling Inhibition of Deactivation of NO-sensitive Guanylyl Cyclase Accounts for the Sensitizing Effect of YC-1 J. Biol. Chem., July 5, 2002; 277(28): 24883 - 24888. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Garthwaite, D. A. Goodwin, S. Neale, D. Riddall, and J. Garthwaite Soluble Guanylyl Cyclase Activator YC-1 Protects White Matter Axons from Nitric Oxide Toxicity and Metabolic Stress, Probably through Na+ Channel Inhibition Mol. Pharmacol., January 1, 2002; 61(1): 97 - 104. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Martin, Y.-C. Lee, and F. Murad YC-1 activation of human soluble guanylyl cyclase has both heme-dependent and heme-independent components PNAS, October 25, 2001; (2001) 231486198. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-E. Andersson Pharmacology of Penile Erection Pharmacol. Rev., September 1, 2001; 53(3): 417 - 450. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Schmidt, A. Schrammel, D. Koesling, and B. Mayer Molecular Mechanisms Involved in the Synergistic Activation of Soluble Guanylyl Cyclase by YC-1 and Nitric Oxide in Endothelial Cells Mol. Pharmacol., February 1, 2001; 59(2): 220 - 224. [Abstract] [Full Text] |
||||
![]() |
B. Tantini, F. Flamigni, C. Pignatti, C. Stefanelli, M. Fattori, A. Facchini, E. Giordano, C. Clo, and C. M. Caldarera Polyamines, NO and cGMP mediate stimulation of DNA synthesis by tumor necrosis factor and lipopolysaccharide in chick embryo cardiomyocytes Cardiovasc Res, February 1, 2001; 49(2): 408 - 416. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-C. Lee, E. Martin, and F. Murad Human recombinant soluble guanylyl cyclase: Expression, purification, and regulation PNAS, September 19, 2000; (2000) 190333697. [Abstract] [Full Text] |
||||
![]() |
T. C. Bellamy, J. Wood, D. A. Goodwin, and J. Garthwaite Rapid desensitization of the nitric oxide receptor, soluble guanylyl cyclase, underlies diversity of cellular cGMP responses PNAS, March 14, 2000; 97(6): 2928 - 2933. [Abstract] [Full Text] [PDF] |